

POWER OF ATTORNEY
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**POWER OF ATTORNEY BY ASSIGNEE
AND EXCLUSION OF INVENTOR(S) UNDER 37 C.F.R. 3.71
WITH STATEMENT UNDER 37 C.F.R. 3.73(b)**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The undersigned assignee of the patents and patent applications listed on Attachment A, hereby appoints Practitioners of Jones Day associated with Customer Number 20583, which mailing address is Jones Day, 222 East 41st Street, New York, New York 10017, as its attorneys to prosecute these applications and to transact all business in the United States Patent and Trademark Office connected therewith, said appointment to be to the exclusion of the inventors and their attorney(s) in accordance with the provisions of 37 C.F.R. 3.71.

Please direct all correspondence for this application to Customer no. 20583.

Statement Under 37 C.F.R. 3.73(b)

L'UNIVERSITÉ MONTPELLIER II states that it is:

- ☐ the assignee of the entire right, title, and interest; or
☒ an assignee of less than the entire right, title and interest.

in the patent applications/patent identified above by virtue of:

- ☒ An assignment agreement dated March 4, 2009. The assignment agreement was recorded in the United States Patent and Trademark Office on May 6, 2009 at Reel 022644, Frame 0923, or for which a copy thereof is attached.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

ASSIGNEE: L'UNIVERSITÉ MONTPELLIER II

Date: 26/05/2009 Signature: _____

Typed Name: DANIELE HERIN

Position/Title: PRESIDENT



[Handwritten signature of Daniele Herin]

Attachment A

<u>Jones Day CAM</u>	<u>Docket No.</u>	<u>Index Ref. No.</u>	<u>Type Related/</u>	<u>Inventor</u>	<u>Serial No.</u>	<u>Filed</u>	<u>Title</u>
417451-888016	11874-016-888	1017 US PROV	PROV	Gosselin, G. Sommadosi, J.-P. Moussa, A. Pierra, C. Benzaria-Prad, S. Dukhan, D. LaColla, P.	60/392,351	6/28/02	2' and 3' Nucleoside Prodrugs for Treating Hepatitis C Virus
417451-999016	11874-016-999	1017 US	11874-015-888 11874-016-888 11874-130-888	LaColla, P. Sommadosi, J.-P. Gosselin, G. Storer, R.	10/609,298	6/27/03	2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999047	11874-047-999	1017 US CON 1	CON of 11874-016-999	Gosselin, G. Storer, R. LaColla, P. Sommadosi, J.-P.	11/005,471	12/6/04	2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999048	11874-048-999	1017 US CON 2	CON of 11874-016-999	Gosselin, G. LaColla, P. Sommadosi, J.-P.	11/005,442	12/6/04	2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999049	11874-049-999	1017 US CON 3	CON of 11874-016-999	Gosselin, G. LaColla, P. Sommadosi, J.-P.	11/005,466	12/6/04	2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999050	11874-050-999	1017 US CON 4	CON of 11874-016-999	Gosselin, G. LaColla, P. Sommadosi, J.-P.	11/005,440	12/6/04	2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999051	11874-051-999	1017 US CON 5	CON of 11874-016-999	Gosselin, G. (Storer, R.) LaColla, A. Sommadosi, J.-P.	11/005,443	12/6/04	2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999052	11874-052-999	1017 US CON 6	CON of 11874-016-999	Gosselin, G. LaColla, A. Sommadosi, J.-P.	11/005,446	12/6/04	2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999053	11874-053-999	1017 US CON 7	CON of 11874-016-999	Gosselin, G. LaColla, A. Sommadosi, J.-P.	11/005,472	12/6/04	2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999054	11874-054-999	1017 US CON 8	CON of 11874-016-999	Gosselin, G. LaColla, A. Sommadosi, J.-P.	11/005,444	12/6/04	2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections

<u>Jones Day CAM</u>	<u>Docket No.</u>	<u>Identif. Ref. No.</u>	<u>Type Related/</u>	<u>Inventor</u>	<u>Serial No.</u>	<u>Filed</u>	<u>Title</u>
417451-888055	11874-055-888	1018 US PROV	PROV	Storer, R. Gosselin, G. Sommadossi, J.-P. Moussa, A. LaColla, P.	60/392,350	6/28/02	Modified 2' and 3' Nucleoside Prodrugs for Treating Hepatitis C Virus
417451-999055	11874-055-999	1018 US	11874-015-888 11874-055-888 11874-130-888	Storer, R. Gosselin, G. LaColla, P. Sommadossi, J.-P.	10/608,907	6/27/03	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999056	11874-056-999	1018 US CON 1	CON of 11874-055-999	LaColla, P. Storer, R. Gosselin, G. Sommadossi, J.-P.	11/005,445	12/6/04	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999057	11874-057-999	1018 US CON 2	CON of 11874-055-999	LaColla, P. Storer, R. Gosselin, G. Sommadossi, J.-P.	11/005,473	12/6/04	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999058	11874-058-999	1018 US CON 3	CON of 11874-055-999	Storer, R. Gosselin, G. LaColla, P. Sommadossi, J.-P.	11/005,468	12/6/04	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999059	11874-059-999	1018 US CON 4	CON of 11874-055-999	LaColla, P. Storer, R. Gosselin, G. Sommadossi, J.-P.	11/005,467	12/6/04	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999060	11874-060-999	1018 US CON 5	CON of 11874-055-999	LaColla, P. Storer, R. Gosselin, G. Sommadossi, J.-P.	11/005,470	12/6/04	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999061	11874-061-999	1018 US CON 6	CON of 11874-055-999	Storer, R. Gosselin, G. LaColla, P. Sommadossi, J.-P.	11/005,447	12/6/04	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999062	11874-062-999	1018 US CON 7	CON of 11874-055-999	Storer, R. Gosselin, G. LaColla, P. Sommadossi, J.-P.	11/005,441	12/6/04	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections

<u>Jones Day CAM</u>	<u>Docket No.</u>	<u>Index Ref. No.</u>	<u>Type Related/</u>	<u>Inventor</u>	<u>Serial No.</u>	<u>Filed</u>	<u>Title</u>
417451-999063	11874-063-999	1018 US CON 8	CON of 11874-055-999	LaColla, P. Storer, R. Gosselin, G. Sommadossi, J.-P.	11/005,469	12/6/04	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999190	11874-190-999	1018 US DIV	DIV of 11874- 055-999	LaColla, P. Storer, R. Gosselin, G. Sommadossi, J.-P.	12/131,868	6/2/08	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999026	11874-026-999	1031 US	11874-016-888 11874-130-888	Sommadossi, J.-P. La Colla, P. Gosselin, G.	10/607,909	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-999086	11874-086-999	1031 US CON 1	CON of 11874-026-999	Sommadossi, J.-P. Gosselin, G. LaColla, P.	11/516,928	9/6/06	2'-C-Methyl-3'-O-L-Valine Ester Ribofuranosyl Cytidine for Treatment of Flaviviridae Infections
417451-888077	11874-077-888	1040 US PROV	PROV	Gosselin, G. Seela, F. LaColla, P. Storer, R. Dukhan, D. Leroy, F.	60/582,182	6/23/04	5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae
417451-999077	11874-077-999	1040 US	11874-077-888	Gosselin, G. Seela, F. LaColla, P. Storer, R. Dukhan, D. Leroy, F.	11/166,498	6/23/05	5-Aza-7-Deazapurine Derivatives for Treating Flaviviridae